AU2002251763B2 - Method for treating cancer - Google Patents

Method for treating cancer Download PDF

Info

Publication number
AU2002251763B2
AU2002251763B2 AU2002251763A AU2002251763A AU2002251763B2 AU 2002251763 B2 AU2002251763 B2 AU 2002251763B2 AU 2002251763 A AU2002251763 A AU 2002251763A AU 2002251763 A AU2002251763 A AU 2002251763A AU 2002251763 B2 AU2002251763 B2 AU 2002251763B2
Authority
AU
Australia
Prior art keywords
administered
combination
agents
administration
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002251763A
Other languages
English (en)
Other versions
AU2002251763A1 (en
Inventor
Frederick H. Hausheer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BioNumerik Pharmaceuticals Inc
Original Assignee
BioNumerik Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BioNumerik Pharmaceuticals Inc filed Critical BioNumerik Pharmaceuticals Inc
Publication of AU2002251763A1 publication Critical patent/AU2002251763A1/en
Application granted granted Critical
Publication of AU2002251763B2 publication Critical patent/AU2002251763B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002251763A 2001-01-19 2002-01-11 Method for treating cancer Ceased AU2002251763B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26312701P 2001-01-19 2001-01-19
US60/263,127 2001-01-19
PCT/US2002/000943 WO2002056755A2 (en) 2001-01-19 2002-01-11 Method for treating cancer

Publications (2)

Publication Number Publication Date
AU2002251763A1 AU2002251763A1 (en) 2003-02-13
AU2002251763B2 true AU2002251763B2 (en) 2006-05-04

Family

ID=23000486

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002251763A Ceased AU2002251763B2 (en) 2001-01-19 2002-01-11 Method for treating cancer

Country Status (6)

Country Link
EP (1) EP1351677A4 (es)
JP (2) JP2004523518A (es)
AU (1) AU2002251763B2 (es)
CA (1) CA2434270A1 (es)
MX (1) MXPA03006359A (es)
WO (1) WO2002056755A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710095B2 (en) 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
CA3054535A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
JP5694782B2 (ja) * 2008-03-14 2015-04-01 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド 肺癌、腺癌及び他の病状のための治療方法及び組成物
WO2009113989A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
AU2008352598B2 (en) * 2008-03-14 2012-06-07 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902610A (en) * 1994-11-14 1999-05-11 Bionumerik Pharmaceuticals, Inc. Formulations and methods of use of 2,2'-dithio-bis-ethane sulfonate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
DK0957920T3 (da) * 1996-09-23 2002-04-02 Bionumerik Pharmaceuticals Inc Reduktion af carboplatins toksiske effekt under anvendelse af dithioethere

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902610A (en) * 1994-11-14 1999-05-11 Bionumerik Pharmaceuticals, Inc. Formulations and methods of use of 2,2'-dithio-bis-ethane sulfonate

Also Published As

Publication number Publication date
JP2004523518A (ja) 2004-08-05
EP1351677A4 (en) 2009-08-19
JP2009292837A (ja) 2009-12-17
MXPA03006359A (es) 2004-04-20
CA2434270A1 (en) 2002-07-25
WO2002056755A2 (en) 2002-07-25
WO2002056755A3 (en) 2002-09-26
EP1351677A2 (en) 2003-10-15

Similar Documents

Publication Publication Date Title
RU2767664C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
RU2587013C2 (ru) Комбинированная химиотерапия
KR100718946B1 (ko) 효과적인 항종양 치료
EP1173187B1 (en) Combined preparations comprising morpholine anthracyclines and platinum derivatives
JP2011140521A (ja) タキサンにより惹起される神経毒性を予防又は軽減するための薬剤
Abou-Jawde et al. Efficacy and safety results with the combination therapy of arsenic trioxide, dexamethasone, and ascorbic acid in multiple myeloma patients: a phase 2 trial
AU2012257760A1 (en) Method for treatment of advanced solid tumors
US6596320B1 (en) Method for treating cancer having greater efficacy and reduced adverse effects
JP2009292837A (ja) より効能が大きく副作用の少ない癌治療方法
JP2009536956A (ja) 抗癌治療法
JPS6287516A (ja) 悪性腫瘍の生体外での処置法
JP2007511509A (ja) Ｅｔ−７４３およびパクリタキセルの使用を含むガンの併用療法
AU2002251763A1 (en) Method for treating cancer
Hainsworth et al. Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma
JP2006528696A (ja) 抗癌剤の抗腫瘍活性を増強する方法
MXPA04006822A (es) Combinaciones que comprenden epotilonas y anti-metabolitos.
US6939893B2 (en) Method of reducing toxicity of anticancer agents
KR20030015829A (ko) 배합 화학요법
AU774393B2 (en) Anti-tumor synergetic composition
JP2006527753A (ja) 結腸直腸癌などの治療のための、血管損傷効果を有する、５−ｆｕ、ｃｐｔ−１１または５−ｆｕおよびｃｐｔ−１１と組み合わせたｚｄ６１２６を含んでなる組成物
MX2011006253A (es) Combinacion antitumoral que asocia ave8062 y docetaxel.
Büntzel et al. Cytoprotection as a New Supportive Strategy in the Treatment of Solid Tumors
Nabholtz Share this story: RELATED ARTICLES
WO2008033039A1 (en) Cancer treatment
MXPA06005359A (es) Terapia de combinacion que comprende el uso de et-743 y paclitaxel para tratar el cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired